Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001104659-13-026212
Filing Date
2013-04-01
Accepted
2013-04-01 17:03:33
Documents
14
Period of Report
2012-12-31

Document Format Files

Seq Description Document Type Size
1 10-K a13-9040_110k.htm 10-K 1956132
2 EX-31.1 a13-9040_1ex31d1.htm EX-31.1 11103
3 EX-31.2 a13-9040_1ex31d2.htm EX-31.2 11158
4 EX-32.1 a13-9040_1ex32d1.htm EX-32.1 5303
5 EX-32.2 a13-9040_1ex32d2.htm EX-32.2 5313
6 GRAPHIC g90401bei001.jpg GRAPHIC 9644
7 GRAPHIC g90401bei002.jpg GRAPHIC 13107
8 GRAPHIC g90401bai001.jpg GRAPHIC 9572
9 GRAPHIC g90401bai002.gif GRAPHIC 45654
10 GRAPHIC g90401bci001.jpg GRAPHIC 11031
11 GRAPHIC g90401bci002.jpg GRAPHIC 11852
12 GRAPHIC g90401bci003.jpg GRAPHIC 11325
13 GRAPHIC g90401bci004.jpg GRAPHIC 13581
14 GRAPHIC g90401bci005.jpg GRAPHIC 7745
  Complete submission text file 0001104659-13-026212.txt   2175261
Mailing Address 750 LEXINGTON AVENUE NEW YORK NY 10022
Business Address 750 LEXINGTON AVENUE NEW YORK NY 10022 212-831-1111
STEMLINE THERAPEUTICS INC (Filer) CIK: 0001264587 (see all company filings)

EIN.: 450522567 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-35619 | Film No.: 13732063
SIC: 2834 Pharmaceutical Preparations